Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 0431, Mk
2. 4-oxo-4-(3-(trifluoromethyl)-5,6-dihydro(1,2,4)triazolo(4,3-a)pyrazin-7(8h)-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine
3. Anhydrous, Sitagliptin Phosphate
4. Januvia
5. Mk 0431
6. Mk-0431
7. Mk0431
8. Monohydrate, Sitagliptin Monophosphate
9. Monohydrate, Sitagliptin Phosphate
10. Monophosphate Monohydrate, Sitagliptin
11. Phosphate Anhydrous, Sitagliptin
12. Phosphate Monohydrate, Sitagliptin
13. Phosphate, Sitagliptin
14. Sitagliptin
15. Sitagliptin Monophosphate Monohydrate
16. Sitagliptin Phosphate Anhydrous
17. Sitagliptin Phosphate Monohydrate
1. 654671-78-0
2. Sitagliptin (phosphate)
3. Mk-0431
4. Chembl393336
5. 494p4635i6
6. Mk0431
7. (2r)-4-oxo-4-(3-(trifluoromethyl)-5,6-dihydro(1,2,4)triazolo(4,3-a)pyrazin-7(8h)-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine Phosphate Salt
8. (3r)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5h-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one;phosphoric Acid
9. (r)-3-amino-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8h)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one Phosphate
10. 1-butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8h)-yl]-4-(2,4,5-trifluorophenyl)-, (3r)-, Phosphate (1:1)
11. Sitagliptin Monophosphate
12. Sitagliptin Phosphate Anhydrous
13. (3r)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5h-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)-1-butanone; Phosphoric Acid
14. Mk 0431
15. Sr-05000001748
16. Unii-494p4635i6
17. (2r)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8h)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine Phosphate Salt
18. Mk 431
19. Mk-0431 Phosphate
20. Schembl877069
21. Dtxsid10215789
22. Hy-13749a
23. Mfcd09952339
24. Akos015896098
25. Sitagliptin Phosphate [who-dd]
26. Ks-1214
27. 4-oxo-4-(3-(trifluoromethyl)-5,6-dihydro(1,2,4)triazolo(4,3-a)pyrazin-7(8h)-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine Phosphate
28. Sitagliptin Monophosphate Anhydrous [mi]
29. 671s780
30. A835125
31. Sr-05000001748-2
32. Q27259224
33. Sitagliptin Phosphate Anhydrous Component Of Janumet
34. (3r)-3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8h)-yl]-4-(2,4,5-trifluorophenyl)-1-butanone Phosphate
35. (3r)-3-azanyl-1-[3-(trifluoromethyl)-6,8-dihydro-5h-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-[2,4,5-tris(fluoranyl)phenyl]butan-1-one; Phosphoric Acid
36. 1,2,4-triazolo(4,3-a)pyrazine, 7-((3r)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl)-5,6,7,8-tetrahydro-3-(trifluoromethyl)-, Phosphate (1:1)
37. 1269630-53-6
38. 7-((3r)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo(4,3-a)pyrazinemonophosphate
39. 7-(3r)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine Phosphate
| Molecular Weight | 505.31 g/mol |
|---|---|
| Molecular Formula | C16H18F6N5O5P |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 14 |
| Rotatable Bond Count | 4 |
| Exact Mass | 505.09497466 g/mol |
| Monoisotopic Mass | 505.09497466 g/mol |
| Topological Polar Surface Area | 155 Ų |
| Heavy Atom Count | 33 |
| Formal Charge | 0 |
| Complexity | 616 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 4 | |
|---|---|
| Drug Name | Januvia |
| PubMed Health | Sitagliptin (By mouth) |
| Drug Classes | Antidiabetic |
| Drug Label | JANUVIA Tablets contain sitagliptin phosphate, an orally-active inhibitor of the dipeptidyl peptidase-4 (DPP-4) enzyme. Sitagliptin phosphate monohydrate is described chemically as 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahy... |
| Active Ingredient | Sitagliptin phosphate |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | eq 100mg base; eq 50mg base; eq 25mg base |
| Market Status | Prescription |
| Company | Merck Sharp Dohme |
| 2 of 4 | |
|---|---|
| Drug Name | Sitagliptin phosphate |
| Active Ingredient | Sitagliptin phosphate |
| Dosage Form | Tablet |
| Route | oral; Oral |
| Strength | eq 100mg base; 25mg; eq 50mg base; 100mg; 50mg; eq 25mg base |
| Market Status | Tentative Approval |
| Company | Mylan Pharms; Apotex; Sandoz; Sun Pharma Global; Watson Labs |
| 3 of 4 | |
|---|---|
| Drug Name | Januvia |
| PubMed Health | Sitagliptin (By mouth) |
| Drug Classes | Antidiabetic |
| Drug Label | JANUVIA Tablets contain sitagliptin phosphate, an orally-active inhibitor of the dipeptidyl peptidase-4 (DPP-4) enzyme. Sitagliptin phosphate monohydrate is described chemically as 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahy... |
| Active Ingredient | Sitagliptin phosphate |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | eq 100mg base; eq 50mg base; eq 25mg base |
| Market Status | Prescription |
| Company | Merck Sharp Dohme |
| 4 of 4 | |
|---|---|
| Drug Name | Sitagliptin phosphate |
| Active Ingredient | Sitagliptin phosphate |
| Dosage Form | Tablet |
| Route | oral; Oral |
| Strength | eq 100mg base; 25mg; eq 50mg base; 100mg; 50mg; eq 25mg base |
| Market Status | Tentative Approval |
| Company | Mylan Pharms; Apotex; Sandoz; Sun Pharma Global; Watson Labs |
Hypoglycemic Agents
Substances which lower blood glucose levels. (See all compounds classified as Hypoglycemic Agents.)
Incretins
Peptides which stimulate INSULIN release from the PANCREATIC BETA CELLS following oral nutrient ingestion, or postprandially. (See all compounds classified as Incretins.)
Dipeptidyl-Peptidase IV Inhibitors
Compounds that suppress the degradation of INCRETINS by blocking the action of DIPEPTIDYL-PEPTIDASE IV. This helps to correct the defective INSULIN and GLUCAGON secretion characteristic of TYPE 2 DIABETES MELLITUS by stimulating insulin secretion and suppressing glucagon release. (See all compounds classified as Dipeptidyl-Peptidase IV Inhibitors.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Sitagliptin Phosphate Monohydrate
Certificate Number : R0-CEP 2021-155 - Rev 00
Status : Valid
Issue Date : 2022-05-20
Type : Chemical
Substance Number : 2778
AMI Lifesciences is Driven by Chemistry. Powered by People.
AMI Lifesciences is Driven by Chemistry. Powered by People.
Sitagliptin Phosphate Monohydrate, Process II
Certificate Number : CEP 2024-249 - Rev 00
Status : Valid
Issue Date : 2024-12-19
Type : Chemical
Substance Number : 2778
AMI Lifesciences is Driven by Chemistry. Powered by People.
AMI Lifesciences is Driven by Chemistry. Powered by People.
Sitagliptin Phosphate Monohydrate
Certificate Number : CEP 2022-340 - Rev 00
Status : Valid
Issue Date : 2024-05-06
Type : Chemical
Substance Number : 2778
Honour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.
Honour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.
Sitagliptin Phosphate Monohydrate
Certificate Number : CEP 2016-324 - Rev 01
Status : Valid
Issue Date : 2024-12-16
Type : Chemical
Substance Number : 2778
Sitagliptin Phosphate Monohydrate
Certificate Number : R0-CEP 2020-197 - Rev 00
Status : Valid
Issue Date : 2023-08-11
Type : Chemical
Substance Number : 2778
Sitagliptin Phosphate Monohydrate
Certificate Number : R0-CEP 2021-295 - Rev 00
Status : Valid
Issue Date : 2023-08-25
Type : Chemical
Substance Number : 2778
Sitagliptin Phosphate Monohydrate
Certificate Number : R0-CEP 2021-175 - Rev 00
Status : Valid
Issue Date : 2023-08-31
Type : Chemical
Substance Number : 2778
Sitagliptin Phosphate Monohydrate, Crystalline F...
Certificate Number : CEP 2016-262 - Rev 01
Status : Valid
Issue Date : 2024-01-12
Type : Chemical
Substance Number : 2778
Sitagliptin Phosphate Monohydrate
Certificate Number : R0-CEP 2017-252 - Rev 00
Status : Valid
Issue Date : 2021-01-28
Type : Chemical
Substance Number : 2778
Sitagliptin Phosphate Monohydrate
Certificate Number : R0-CEP 2021-228 - Rev 00
Status : Valid
Issue Date : 2023-07-12
Type : Chemical
Substance Number : 2778
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
Delivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.
RLD :
TE Code :
Brand Name : SITAGLIPTIN
Dosage Form : TABLET; FILM COATED
Dosage Strength : 25MG
Approval Date :
Application Number : 216919
RX/OTC/DISCN :
RLD :
TE Code :
Delivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.
RLD :
TE Code :
Brand Name : SITAGLIPTIN
Dosage Form : TABLET; FILM COATED
Dosage Strength : 50MG
Approval Date :
Application Number : 216919
RX/OTC/DISCN :
RLD :
TE Code :
Delivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.
RLD :
TE Code :
Brand Name : SITAGLIPTIN
Dosage Form : TABLET; FILM COATED
Dosage Strength : 100MG
Approval Date :
Application Number : 216919
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : SITAGLIPTIN PHOSPHATE
Dosage Form : TABLET;ORAL
Dosage Strength : 50MG
Approval Date :
Application Number : 202327
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : SITAGLIPTIN PHOSPHATE
Dosage Form : TABLET;ORAL
Dosage Strength : 100MG
Approval Date :
Application Number : 202327
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : SITAGLIPTIN PHOSPHATE
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 50MG BASE
Approval Date :
Application Number : 214784
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
METFORMIN HYDROCHLORIDE; SITAGLIPTIN
Brand Name : METFORMIN HYDROCHLORIDE AND SITAGLIPTIN PHOSPHATE
Dosage Form : TABLET;FILM COATED
Dosage Strength : 1000MG
Approval Date :
Application Number : 212338
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
SITAGLIPTIN; METFORMIN HYDROCHLORIDE
Brand Name : SITAGLIPTIN; METFORMIN HYDROCHLORIDE
Dosage Form : TABLET; ORAL
Dosage Strength : 50MG; 500MG
Approval Date :
Application Number : 202388
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
SITAGLIPTIN; METFORMIN HYDROCHLORIDE
Brand Name : SITAGLIPTIN; METFORMIN HYDROCHLORIDE
Dosage Form : TABLET; ORAL
Dosage Strength : 50MG; 1000MG
Approval Date :
Application Number : 202388
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : SITAGLIPTIN PHOSPHATE
Dosage Form : TABLET; ORAL
Dosage Strength : EQ 50MG BASE
Approval Date :
Application Number : 202473
RX/OTC/DISCN :
RLD :
TE Code :
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - TABLET;ORAL - EQ 100MG BASE
USFDA APPLICATION NUMBER - 21995
DOSAGE - TABLET;ORAL - EQ 25MG BASE
USFDA APPLICATION NUMBER - 21995
DOSAGE - TABLET;ORAL - EQ 50MG BASE
USFDA APPLICATION NUMBER - 21995
DOSAGE - TABLET;ORAL - 1GM;EQ 50MG BASE
USFDA APPLICATION NUMBER - 22044
DOSAGE - TABLET;ORAL - 500MG;EQ 50MG BASE
USFDA APPLICATION NUMBER - 22044
Related Excipient Companies
Minakem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Faran Shimi Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Boai NKY Pharmaceuticals Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Minbiotech
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ACG Worldwide
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Aeon Procare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ashland
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kima Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lonza Capsugel
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nomisma Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Novo Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qianhao Chemical (Hebei) Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qualicaps
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Welltone Material Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Silverline Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]The Dow Chemical Company
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ulanqab Kema New Material
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Coating Systems & Additives
Fillers, Diluents & Binders
Controlled & Modified Release
Lubricants & Glidants
Thickeners and Stabilizers
Disintegrants & Superdisintegrants
Granulation
Direct Compression
Topical
Co-Processed Excipients
Film Formers & Plasticizers
API Stability Enhancers
Solubilizers
Taste Masking
Rheology Modifiers
Empty Capsules
Coloring Agents
Emulsifying Agents
Chewable & Orodispersible Aids
Vegetarian Capsules
Parenteral
Surfactant & Foaming Agents
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
USP
ANALYTICAL
ABOUT THIS PAGE
22
PharmaCompass offers a list of Sitagliptin Phosphate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Sitagliptin Phosphate manufacturer or Sitagliptin Phosphate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Sitagliptin Phosphate manufacturer or Sitagliptin Phosphate supplier.
PharmaCompass also assists you with knowing the Sitagliptin Phosphate API Price utilized in the formulation of products. Sitagliptin Phosphate API Price is not always fixed or binding as the Sitagliptin Phosphate Price is obtained through a variety of data sources. The Sitagliptin Phosphate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Sitagliptin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Sitagliptin, including repackagers and relabelers. The FDA regulates Sitagliptin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Sitagliptin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Sitagliptin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Sitagliptin supplier is an individual or a company that provides Sitagliptin active pharmaceutical ingredient (API) or Sitagliptin finished formulations upon request. The Sitagliptin suppliers may include Sitagliptin API manufacturers, exporters, distributors and traders.
click here to find a list of Sitagliptin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Sitagliptin DMF (Drug Master File) is a document detailing the whole manufacturing process of Sitagliptin active pharmaceutical ingredient (API) in detail. Different forms of Sitagliptin DMFs exist exist since differing nations have different regulations, such as Sitagliptin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Sitagliptin DMF submitted to regulatory agencies in the US is known as a USDMF. Sitagliptin USDMF includes data on Sitagliptin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Sitagliptin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Sitagliptin suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Sitagliptin Drug Master File in Japan (Sitagliptin JDMF) empowers Sitagliptin API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Sitagliptin JDMF during the approval evaluation for pharmaceutical products. At the time of Sitagliptin JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Sitagliptin suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Sitagliptin Drug Master File in Korea (Sitagliptin KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Sitagliptin. The MFDS reviews the Sitagliptin KDMF as part of the drug registration process and uses the information provided in the Sitagliptin KDMF to evaluate the safety and efficacy of the drug.
After submitting a Sitagliptin KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Sitagliptin API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Sitagliptin suppliers with KDMF on PharmaCompass.
A Sitagliptin CEP of the European Pharmacopoeia monograph is often referred to as a Sitagliptin Certificate of Suitability (COS). The purpose of a Sitagliptin CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Sitagliptin EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Sitagliptin to their clients by showing that a Sitagliptin CEP has been issued for it. The manufacturer submits a Sitagliptin CEP (COS) as part of the market authorization procedure, and it takes on the role of a Sitagliptin CEP holder for the record. Additionally, the data presented in the Sitagliptin CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Sitagliptin DMF.
A Sitagliptin CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Sitagliptin CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Sitagliptin suppliers with CEP (COS) on PharmaCompass.
A Sitagliptin written confirmation (Sitagliptin WC) is an official document issued by a regulatory agency to a Sitagliptin manufacturer, verifying that the manufacturing facility of a Sitagliptin active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Sitagliptin APIs or Sitagliptin finished pharmaceutical products to another nation, regulatory agencies frequently require a Sitagliptin WC (written confirmation) as part of the regulatory process.
click here to find a list of Sitagliptin suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Sitagliptin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Sitagliptin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Sitagliptin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Sitagliptin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Sitagliptin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Sitagliptin suppliers with NDC on PharmaCompass.
Sitagliptin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Sitagliptin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Sitagliptin GMP manufacturer or Sitagliptin GMP API supplier for your needs.
A Sitagliptin CoA (Certificate of Analysis) is a formal document that attests to Sitagliptin's compliance with Sitagliptin specifications and serves as a tool for batch-level quality control.
Sitagliptin CoA mostly includes findings from lab analyses of a specific batch. For each Sitagliptin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Sitagliptin may be tested according to a variety of international standards, such as European Pharmacopoeia (Sitagliptin EP), Sitagliptin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Sitagliptin USP).
